Pharma BD Deal Intelligence
Hi-Tech CEO David Seltzer said the transaction 'delivers compelling value to our shareholders'; the deal positions the combined entity as the third-largest…
AAO noted the acquisition strengthens Akorn's position as the third-largest US generic ophthalmic player while broadening the offering into oral liquids,…
Zacks rated Akorn a #2 (Buy) at announcement and Hi-Tech a #5 (Strong Sell), framing the deal as a buyer-favorable consolidation that strengthens Akorn's…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Akorn to acquire Hi-Tech Pharmacal at $43.50/share cash (~$640M; 23.5% premium); $15-20M expected annual synergies; expanded sterile/specialty generic dosage form capabilities.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Akorn, Inc. / Hi-Tech Pharmacal Co. Inc. (this deal) | 2013 | $640M | 28 |
| Akorn, Inc. / VPI Holdings Corp. (VersaPharm Incorporated) | 2014 | $440M | 14 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2013 deals · Other deals